Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer
Bao, G.; Yang, D.-q.; Zhou, B.; Liu, P.; Wang, S.; Cheng, L.
Zhonghua Yi Xue Za Zhi 87(40): 2843-2845
2007
ISSN/ISBN: 0376-2491 PMID: 18167290 Document Number: 608593
To study the effect to neoadjuvant chemotherapy on estrogen receptor (ER), progesterone receptor (PR), P53 and CerbB-2 expression in patients with breast cancer. From 123 breast cancer patients treated with neoadjuvant chemotherapy, core needle biopsy samples before the chemotherapy and surgical specimens were obtained for assay of ER, PR, P53 and CerbB-2 expression. ER expression occurred in 46.61% (55/118) of the patients before neoadjuvant chemotherapy and in 66.10% (78/118) of these after surgery showing statistically significant. But the changes in PR, P53 and CerbB-2 expression exhibited no significant difference. Significant changes occur in ER expression after neoadjuvant chemotherapy in patients with breast cancer. Neoadjuvant chemotherapy has no significant effects on PR, P53 and CerbB-2 expression in patients with breast cancer.